Nature Biotechnology Article Provides Advice On Addressing The New Risks Pharma And Biotech Companies Face From Payers' Focus On the Healthcare Value of Biologicals

Published: Feb 13, 2008

WAKEFIELD, Mass.--(BUSINESS WIRE)--The Bruckner Group is pleased to announce the publication in Nature Biotechnology of an expansive feature article in the February 2008 issue, written by Bruckner Group partners Michael Russo and David Balekdjian. The article, “Weighing the Outcomes,” explores how the intensification of managed care and employer influence over patient access to biological drugs is presenting new risks for pharma and biotech companies, and provides advice on what companies can do about it. “Weighing the Outcomes” is a white paper on creating enterprise-wide change in pharma and biotech companies. To remain competitive, companies must centralize the development and commercialization of drugs with compelling healthcare value as a mission-critical organizational necessity.

Back to news